Psychedelic compound ibogaine may be option for treatment of opioid addiction | Health

Federal Research Push Follows High-Profile Scrutiny Over Ibogaine Therapy

Ibogaine, a psychoactive compound extracted from an African shrub, is drawing renewed federal attention and strict regulatory hurdles following its rise in popularity as an alternative addiction treatment, phillytrib.com reported. The substance currently faces a federal ban in the United States while researchers evaluate its potential utility against opioid dependence and severe mental health conditions.

The debate surrounding the psychoactive plant intensified after Presley Gerber, a mental health advocate and son of supermodel Cindy Crawford, died at age 27 at a California rehabilitation facility. The Santa Monica Police Department is investigating Gerber’s death as a suspected overdose, though law enforcement officials have not yet confirmed a formal cause or manner of death. Gerber had publicly mentioned undergoing a pre-ibogaine flood dose in a March social media post.

Executive Action Aims to Fast-Track Psychedelic Studies

President Donald Trump signed an executive order in April directing federal agencies to fast-track research and clinical access to psychedelic compounds, allocating $50 million to state governments for mental illness studies. The directive explicitly identifies ibogaine compounds as holding potential for treating serious psychiatric illnesses. Dr. Marty Makary, who was then FDA commissioner, stated that the agency could review late-stage clinical trial data to determine future approvals.

Despite federal interest, the U.S. Drug Enforcement Administration currently classifies ibogaine as a Schedule I substance, denoting no accepted medical use and a high abuse potential. Makary noted that any eventual approval would require strict administration within hospital or clinic settings rather than through traditional retail pharmacies. In April, the FDA accepted an investigational new drug application for an ibogaine derivative intended to preserve therapeutic benefits while avoiding hallucinogenic effects and cardiac toxicity.

Historical Path and Clinical Mechanisms of Ibogaine

Anthropologists trace the discovery of ibogaine to Central Africa’s Pygmy people, who utilized the iboga plant in sacred rituals. U.S. researchers first investigated the compound for substance use disorders in 1962 before the DEA placed it under Schedule I restrictions in 1967. Modern researchers, including Dr. Kirsten Cherian of Stanford University, indicate that the drug operates across multiple neurotransmitter systems to temporarily increase neural plasticity and reorganize brain networks.

However, medical professionals urge caution due to significant safety risks. Dr. Arnt Schellekens, a researcher at Radboud University in the Netherlands, characterizes evidence supporting ibogaine as modest and warns of potential dangers, including abnormal heart rhythms and sudden cardiac arrest. Clinical trials remain necessary to establish definitive safety profiles.

Military Veterans Seek Unregulated Treatment Abroad

A growing number of American military veterans travel to countries like Mexico, where ibogaine remains unregulated, to seek treatment for traumatic brain injuries and post-traumatic stress disorder. Organizations such as Veterans Exploring Treatment Solutions have funded treatments exceeding $5,000 for more than 1,300 veterans who exhausted conventional medical options.

While advocates emphasize transformative personal outcomes, public health officials continue to debate whether federal funding initiatives and national priority vouchers will adequately address the complex research requirements and healthcare infrastructure needed for safe mainstream integration.